Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients-Reference-Cited by-同舟云学术

Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients

Published:2021-08-03 Issue:4 Volume:195 Page:523-531
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Benda Magdalena¹²,Mutschlechner Beatrix²³,Ulmer Hanno⁴,Grabher Claudia⁵,Severgnini Luciano¹,Volgger Andreas¹,Reimann Patrick¹,Lang Theresia¹,Atzl Michele¹,Huynh Minh¹,Gasser Klaus¹,Petrausch Ulf⁶⁷,Fraunberger Peter⁵,Hartmann Bernd¹,Winder Thomas¹⁶^ORCID

Affiliation:

1. Department of Internal Medicine II Feldkirch Academic Teaching Hospital FeldkirchAustria

2. Private University of the Principality of Liechtenstein Triesen Principality of Liechtenstein

3. Department of Internal Medicine I Feldkirch Academic Teaching Hospital FeldkirchAustria

4. Department of Medical Statistics, Informatics and Health Economics Innsbruck Medical University InnsbruckAustria

5. Medical Central Laboratories Feldkirch Austria

6. University of Zurich ZurichSwitzerland

7. Onkozentrum Zürich Swiss Tumor Immunology Institute Zurich Switzerland

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17743

Reference23 articles.

1. Johns Hopkins University Coronavirus Resource Center.COVID‐19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University;2020. Available from:https://coronavirus.jhu.edu/map.html.

2. Patients with cancer appear more vulnerable to SARS‐CoV‐2: A multicenter study during the COVID‐19 outbreak;Dai M;Cancer Discov,2020

3. Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

5. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients;Vaccine;2024-01

2. Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL;2023-09-26

3. Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study;Pharmacological Reports;2023-09-01

4. Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies;Journal of Clinical Medicine;2023-08-30

5. Anticuerpos contra el SARS-CoV-2 tras la dosis de vacuna de recuerdo. Identificación de subgrupos con respuesta insuficiente;Revista Clínica Española;2023-06